Kronos Bio Inc. (KRON) NASDAQ
$0.96 0.01 (1.05%)
Market Cap: $57.69M
As of 04/24/24 04:00 PM EDT. Market closed.
Kronos Bio Inc. (KRON)
NASDAQ
$0.96
0.01 (1.05%)
Market Cap: $57.69M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Address
.
PRICE CHART FOR KRONOS BIO INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.97
Previous Close
$0.95
Days Range
$0.96 - $1
52 week range
$0.73 - $2.29
Volume
904,416
Avg. Volume (30 days)
437,122
Market Cap
$57.69M
Dividend Yield
-
P/E
-
Shares Outstanding
60,095,013
Open
$0.97
Previous Close
$0.95
Days Range
$0.96 - $1
52 week range
$0.73 - $2.29
Volume
904,416
Avg. Volume (30 days)
437,122
Market Cap
$57.69M
Dividend Yield
-
P/E
-
Shares Outstanding
60,095,013
FINANCIAL STATEMENTS FOR KRONOS BIO INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR KRONOS BIO INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | Feb 21, 2024 | Sale | $1.05 | 7,368 | 7,765 | 193,275 | Feb 23, 2024, 08:12 PM |
| Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | Feb 21, 2024 | Sale | $1.05 | 12,036 | 12,685 | 234,603 | Feb 23, 2024, 08:07 PM |
| Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | Feb 21, 2024 | Sale | $1.05 | 12,105 | 12,757 | 204,510 | Feb 23, 2024, 08:04 PM |
| Dinsmore Christopher | Chief Scientific Officer | Jan 04, 2024 | Sale | $1.18 | 7,366 | 8,718 | 260,969 | Jan 05, 2024, 06:30 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Jan 04, 2024 | Sale | $1.18 | 12,009 | 14,214 | 315,246 | Jan 05, 2024, 06:27 PM |
| Kosacz Barbara | COO & General Counsel | Jan 04, 2024 | Sale | $1.18 | 10,676 | 12,636 | 928,966 | Jan 05, 2024, 06:26 PM |
| Dinsmore Christopher | Chief Scientific Officer | Dec 12, 2023 | Sale | $1.30 | 10,032 | 13,092 | 268,335 | Dec 13, 2023, 04:10 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Dec 12, 2023 | Sale | $1.30 | 17,367 | 22,664 | 327,255 | Dec 13, 2023, 04:09 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Nov 15, 2023 | Buy | $0.80 | 1,370,688 | 1,102,718 | 2,180,297 | Nov 17, 2023, 05:41 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Nov 17, 2023 | Buy | $1.08 | 97,935 | 106,162 | 2,540,665 | Nov 17, 2023, 05:41 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Nov 16, 2023 | Buy | $1.00 | 262,433 | 261,514 | 2,442,730 | Nov 17, 2023, 05:41 PM |
| Dinsmore Christopher | Chief Scientific Officer | Jul 06, 2023 | Sale | $1.75 | 6,634 | 11,625 | 278,367 | Jul 07, 2023, 04:08 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Jul 06, 2023 | Sale | $1.75 | 10,818 | 18,956 | 344,622 | Jul 07, 2023, 04:07 PM |
| Al-Wakeel Yasir B. | Chief Financial Officer | Jul 06, 2023 | Sale | $1.75 | 9,617 | 16,852 | 346,102 | Jul 07, 2023, 04:06 PM |
| Dinsmore Christopher | Chief Scientific Officer | Feb 24, 2023 | Sale | $1.74 | 6,291 | 10,918 | 285,001 | Feb 24, 2023, 09:36 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Feb 24, 2023 | Sale | $1.74 | 10,153 | 17,621 | 355,440 | Feb 24, 2023, 09:35 PM |
| Al-Wakeel Yasir B. | Chief Financial Officer | Feb 24, 2023 | Sale | $1.74 | 9,026 | 15,665 | 355,719 | Feb 24, 2023, 09:34 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Dec 12, 2022 | Sale | $1.81 | 18,657 | 33,680 | 219,478 | Dec 14, 2022, 04:35 PM |
| Dinsmore Christopher | Chief Scientific Officer | Dec 12, 2022 | Sale | $1.81 | 9,138 | 16,496 | 162,936 | Dec 14, 2022, 04:31 PM |
| BISCHOFBERGER NORBERT W | President & CEO | May 19, 2022 | Buy | $3.78 | 300,000 | 1,134,510 | 809,609 | May 19, 2022, 06:03 PM |
| BISCHOFBERGER NORBERT W | President & CEO | May 18, 2022 | Buy | $3.72 | 206,198 | 768,046 | 509,609 | May 19, 2022, 06:03 PM |
| BISCHOFBERGER NORBERT W | President & CEO | May 17, 2022 | Buy | $3.83 | 90,931 | 348,529 | 303,411 | May 19, 2022, 06:03 PM |
| Dinsmore Christopher | Chief Scientific Officer | Dec 13, 2021 | Sale | $12.37 | 11,386 | 140,845 | 85,148 | Dec 15, 2021, 05:08 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Dec 13, 2021 | Sale | $12.37 | 16,402 | 202,893 | 117,785 | Dec 15, 2021, 05:06 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Dec 06, 2021 | Buy | $12.09 | 14,356 | 173,492 | 212,480 | Dec 08, 2021, 06:21 PM |
| De Backer Marianne | Director | Dec 01, 2021 | Buy | $11.57 | 1,150 | 13,305 | 2,750 | Dec 02, 2021, 05:12 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 04, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Oct 04, 2021, 06:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 04, 2021 | Sale | $20.81 | 9,189 | 191,195 | 96,360 | Oct 04, 2021, 06:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Sep 07, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Sep 09, 2021, 01:23 PM |
| Dinsmore Christopher | Chief Scientific Officer | Sep 07, 2021 | Sale | $21.91 | 9,189 | 201,302 | 96,360 | Sep 09, 2021, 01:23 PM |
| De Backer Marianne | Director | Aug 20, 2021 | Buy | $19.56 | 1,000 | 19,565 | 1,600 | Aug 24, 2021, 07:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Aug 02, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Aug 03, 2021, 05:13 PM |
| Dinsmore Christopher | Chief Scientific Officer | Aug 02, 2021 | Sale | $20.59 | 9,189 | 189,165 | 96,360 | Aug 03, 2021, 05:13 PM |
| Loven Jakob | Director | Apr 20, 2021 | Sale | $20.10 | 21,551 | 433,185 | 1,301,556 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 19, 2021 | Sale | $20.59 | 14,004 | 288,278 | 1,327,245 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 16, 2021 | Sale | $21.01 | 33,162 | 696,762 | 1,344,962 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 15, 2021 | Sale | $21.78 | 24,818 | 540,536 | 1,370,254 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 14, 2021 | Sale | $22.80 | 32,636 | 744,029 | 1,414,010 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 13, 2021 | Sale | $23.84 | 17,020 | 405,793 | 1,434,731 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 12, 2021 | Sale | $26.28 | 15,828 | 415,896 | 1,444,828 | Apr 12, 2021, 08:33 PM |
| Loven Jakob | Director | Apr 09, 2021 | Sale | $27.20 | 21,660 | 589,152 | 1,460,556 | Apr 12, 2021, 08:33 PM |
| Loven Jakob | Director | Apr 08, 2021 | Sale | $27.41 | 63,128 | 1,730,487 | 1,507,032 | Apr 12, 2021, 08:33 PM |
| Omega Fund V, L.P. | 10% Owner | Oct 14, 2020 | Option Exercise | $16.15 | 366,299 | 5,915,729 | 3,368,283 | Oct 16, 2020, 03:58 PM |
| Omega Fund V, L.P. | 10% Owner | Oct 14, 2020 | Buy | $19.00 | 450,000 | 8,550,000 | 3,818,283 | Oct 16, 2020, 03:58 PM |
| Stampacchia Otello | Director | Oct 14, 2020 | Option Exercise | $16.15 | 366,299 | 5,915,729 | 3,368,283 | Oct 16, 2020, 03:56 PM |
| Stampacchia Otello | Director | Oct 14, 2020 | Buy | $19.00 | 450,000 | 8,550,000 | 3,818,283 | Oct 16, 2020, 03:56 PM |
| TANEN DAVID M | Director | Oct 14, 2020 | Option Exercise | $16.15 | 37,119 | 599,472 | 471,230 | Oct 16, 2020, 03:54 PM |
| Ridloff Elena | Director | Oct 14, 2020 | Buy | $19.00 | 2,630 | 49,970 | 2,630 | Oct 16, 2020, 03:52 PM |
| MARTIN JOHN C | Director | Oct 14, 2020 | Option Exercise | $16.15 | 205,260 | 3,314,949 | 1,876,564 | Oct 16, 2020, 03:51 PM |
| MARTIN JOHN C | Director | Oct 14, 2020 | Buy | $19.00 | 75,800 | 1,440,200 | 1,952,364 | Oct 16, 2020, 03:51 PM |
| Loven Jakob | Director | Oct 14, 2020 | Option Exercise | $16.15 | 169,031 | 2,729,851 | 1,545,344 | Oct 16, 2020, 03:49 PM |
| Belldegrun Arie | Director | Oct 14, 2020 | Option Exercise | $16.15 | 253,251 | 4,090,004 | 2,315,314 | Oct 16, 2020, 03:44 PM |
| Kosacz Barbara | COO & General Counsel | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 614,600 | Oct 16, 2020, 03:40 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 5,250 | Oct 16, 2020, 03:39 PM |
| Al-Wakeel Yasir B. | Chief Financial Officer | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 37,219 | Oct 16, 2020, 03:38 PM |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | Oct 14, 2020 | Option Exercise | $16.15 | 185,758 | 2,999,992 | 4,274,996 | Oct 16, 2020, 03:36 PM |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | Oct 14, 2020 | Buy | $19.00 | 95,500 | 1,814,500 | 4,370,496 | Oct 16, 2020, 03:36 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Oct 14, 2020 | Option Exercise | $16.15 | 185,758 | 2,999,992 | 4,274,996 | Oct 16, 2020, 03:29 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Oct 14, 2020 | Buy | $19.00 | 95,500 | 1,814,500 | 4,370,496 | Oct 16, 2020, 03:29 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 02/21/2024 | 7,765 |
| Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | 02/21/2024 | 12,685 |
| Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | 02/21/2024 | 12,757 |
| Dinsmore Christopher | Chief Scientific Officer | 01/04/2024 | 8,718 |
| DiMartino Jorge | Chief Medical Officer & VP | 01/04/2024 | 14,214 |
| Kosacz Barbara | COO & General Counsel | 01/04/2024 | 12,636 |
| Dinsmore Christopher | Chief Scientific Officer | 12/12/2023 | 13,092 |
| DiMartino Jorge | Chief Medical Officer & VP | 12/12/2023 | 22,664 |
| BISCHOFBERGER NORBERT W | President & CEO | 11/15/2023 | 1,102,718 |
| BISCHOFBERGER NORBERT W | President & CEO | 11/17/2023 | 106,162 |
| BISCHOFBERGER NORBERT W | President & CEO | 11/16/2023 | 261,514 |
| Dinsmore Christopher | Chief Scientific Officer | 07/06/2023 | 11,625 |
| DiMartino Jorge | Chief Medical Officer & VP | 07/06/2023 | 18,956 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 07/06/2023 | 16,852 |
| Dinsmore Christopher | Chief Scientific Officer | 02/24/2023 | 10,918 |
| DiMartino Jorge | Chief Medical Officer & VP | 02/24/2023 | 17,621 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 02/24/2023 | 15,665 |
| DiMartino Jorge | Chief Medical Officer & VP | 12/12/2022 | 33,680 |
| Dinsmore Christopher | Chief Scientific Officer | 12/12/2022 | 16,496 |
| BISCHOFBERGER NORBERT W | President & CEO | 05/19/2022 | 1,134,510 |
| BISCHOFBERGER NORBERT W | President & CEO | 05/18/2022 | 768,046 |
| BISCHOFBERGER NORBERT W | President & CEO | 05/17/2022 | 348,529 |
| Dinsmore Christopher | Chief Scientific Officer | 12/13/2021 | 140,845 |
| DiMartino Jorge | Chief Medical Officer & VP | 12/13/2021 | 202,893 |
| BISCHOFBERGER NORBERT W | President & CEO | 12/06/2021 | 173,492 |
| De Backer Marianne | Director | 12/01/2021 | 13,305 |
| Dinsmore Christopher | Chief Scientific Officer | 10/04/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 10/04/2021 | 191,195 |
| Dinsmore Christopher | Chief Scientific Officer | 09/07/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 09/07/2021 | 201,302 |
| De Backer Marianne | Director | 08/20/2021 | 19,565 |
| Dinsmore Christopher | Chief Scientific Officer | 08/02/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 08/02/2021 | 189,165 |
| Loven Jakob | Director | 04/20/2021 | 433,185 |
| Loven Jakob | Director | 04/19/2021 | 288,278 |
| Loven Jakob | Director | 04/16/2021 | 696,762 |
| Loven Jakob | Director | 04/15/2021 | 540,536 |
| Loven Jakob | Director | 04/14/2021 | 744,029 |
| Loven Jakob | Director | 04/13/2021 | 405,793 |
| Loven Jakob | Director | 04/12/2021 | 415,896 |
| Loven Jakob | Director | 04/09/2021 | 589,152 |
| Loven Jakob | Director | 04/08/2021 | 1,730,487 |
| Omega Fund V, L.P. | 10% Owner | 10/14/2020 | 5,915,729 |
| Omega Fund V, L.P. | 10% Owner | 10/14/2020 | 8,550,000 |
| Stampacchia Otello | Director | 10/14/2020 | 5,915,729 |
| Stampacchia Otello | Director | 10/14/2020 | 8,550,000 |
| TANEN DAVID M | Director | 10/14/2020 | 599,472 |
| Ridloff Elena | Director | 10/14/2020 | 49,970 |
| MARTIN JOHN C | Director | 10/14/2020 | 3,314,949 |
| MARTIN JOHN C | Director | 10/14/2020 | 1,440,200 |
| Loven Jakob | Director | 10/14/2020 | 2,729,851 |
| Belldegrun Arie | Director | 10/14/2020 | 4,090,004 |
| Kosacz Barbara | COO & General Counsel | 10/14/2020 | 99,750 |
| Dinsmore Christopher | Chief Scientific Officer | 10/14/2020 | 99,750 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 10/14/2020 | 99,750 |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | 10/14/2020 | 2,999,992 |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | 10/14/2020 | 1,814,500 |
| BISCHOFBERGER NORBERT W | President & CEO | 10/14/2020 | 2,999,992 |
| BISCHOFBERGER NORBERT W | President & CEO | 10/14/2020 | 1,814,500 |
Load More Insider Transactions
FUNDS WITH A POSITION IN KRONOS BIO INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 1,068,504 | 0.00003% | -22.65% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 912,926 | 0.00177% | -8.86% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 428,522 | 0.00006% | 4.44% | Other |
| D. E. SHAW & CO., INC. | 254,987 | 0.00028% | -31.23% | Other |
CHANGE IN SHARES OUTSTANDING FOR KRONOS BIO INC
STOCK BUYBACKS FOR KRONOS BIO INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.22%
1Q
06/30/2023
1.53%
2Q
03/31/2023
1.97%
3Q
12/31/2022
3.09%
4Q
09/30/2022
3.47%
5Q
06/30/2022
3.84%
6Q
03/31/2022
4.36%
7Q
12/31/2021
5.25%
8Q
09/30/2021
6.00%
9Q
06/30/2021
6.91%
10Q
03/31/2021
7.61%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR KRONOS BIO INC
LOADING...